Clarifying the Optimal Application of SLT Therapy Trial

Part of paid clinical trials in Laguna Hills, California.

Sponsor
University of Pittsburgh
Study ID
NCT04967989
Phase
PHASE3
Status
Recruiting

Conditions

  • Glaucoma and Ocular Hypertension

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Low Energy SLT — PROCEDURE
    SLT performed at low energy
  • Standard Energy SLT — PROCEDURE
    SLT performed at standard energy

Study Details

The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.

Key Dates

Start date
Sep 7, 2021
Status verified
Sep 2025
Primary completion
Jun 30, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
790 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Trial 1: Initial standard energy SLT
    Standard energy SLT is performed as follows: beginning at 0.8 mJ, energy will be titrated up or down within the first 5-10 spots until champagne bubbles are visualized with every 2nd or 3rd spot. Energy can be titrated throughout the procedure, in response to variations in pigmentation, to ensure the appearance of champagne bubbles with every 2nd or 3rd spot throughout the full 360° treatment. Energy should be increased if no bubbles are seen with 5 consecutive spots and decreased if bubbles are seen with 5 consecutive spots.
  • Experimental: Trial 2: Month 12 Randomization: Annual Low Energy Repeat SLT
    At month 12, eligible subjects will be randomized to undergo repeat SLT either annually at low energy or as needed at standard energy. Low energy SLT will consist of 100 treatment spots delivered at 0.4 mJ per spot throughout the full 360° treatment, with the exception that energy can be reduced to 0.3 mJ if bubbles are seen with 5 consecutive spots and can be increased back to a maximum of 0.4mJ is no bubbles are seen with 5 consecutive spots.
  • Active Comparator: Trial 2: Month 12 Randomization: As-Needed Repeat SLT at Standard Energy
    At month 12, eligible subjects will be randomized to undergo repeat SLT either annually at low energy or as needed at standard energy. Standard SLT will be performed as follows: beginning at 0.8 mJ, energy will be titrated up or down within the first 5-10 spots until champagne bubbles are visualized with every 2nd or 3rd spot. Energy can be titrated throughout the procedure, in response to variations in pigmentation, to ensure the appearance of champagne bubbles with every 2nd or 3rd spot throughout the full 360° treatment. Energy should be increased if no bubbles are seen with 5 consecutive spots and decreased if bubbles are seen with 5 consecutive spots.
  • Experimental: Trial 1: Initial Low Energy SLT
    Note: This arm was discontinued following a planned interim analysis. Low energy SLT will consist of 100 treatment spots delivered at 0.4 mJ per spot throughout the full 360° treatment, with the exception that energy can be reduced to 0.3 mJ if bubbles are seen with 5 consecutive spots and can be increased back to a maximum of 0.4mJ if no bubbles are seen with 5 consecutive spots.

Primary Outcome Measure

12-month survival [ Time Frame: 12 months ]

Central Contacts

Locations (28)

FacilityCityStateZIPSite coordinators
Harvard Eye AssociatesLaguna HillsCalifornia92653
Jasmin Kaur
949-951-2020
Ye Elaine Wang, MD (PRINCIPAL_INVESTIGATOR)
Doheny Eye Center UCLAPasadenaCalifornia91105
Mayra Raygoza
(626) 817-4747
Judy L Chen, MD (PRINCIPAL_INVESTIGATOR)
University of California, DavisSacramentoCalifornia95817
Leslie Valverde
916-734-6302
James Brandt, MD (PRINCIPAL_INVESTIGATOR)
University of California, San FranciscoSan FranciscoCalifornia94158
Jenny Lu
(415) 476-5321
Ying Han, MD (PRINCIPAL_INVESTIGATOR)
Mile High Eye InstituteSheridanColorado80110
Michelle Lopez Galindo
303-241-7310
Zachary Vest, MD (PRINCIPAL_INVESTIGATOR)
Clear Vue Laser Eye CenterLakeworthFlorida33467
Michelle Hill
561-432-4141
Monique Barbour, MD (PRINCIPAL_INVESTIGATOR)
Northwestern Medical GroupChicagoIllinois60615
Angela Giliana
312-695-0252
Angelo Tanna, MD (PRINCIPAL_INVESTIGATOR)
Chicago Arbor Eye InstituteOrland ParkIllinois60467
Lorene Rafol
708-249-1026
Richard Quinones, MD (PRINCIPAL_INVESTIGATOR)
Illinois Eye CenterPeoriaIllinois61615
Lori Hendershott
309-213-0664
Sachin Kalarn, MD (PRINCIPAL_INVESTIGATOR)
Wilmer Eye Institute Johns HopkinsBaltimoreMaryland21287
Rucha Thaker
908- 616-1807
Pradeep Ramulu, MD (PRINCIPAL_INVESTIGATOR)
Massachusetts Eye and EarBostonMassachusetts02114
Michael Cheung
Michael Lin, MD (PRINCIPAL_INVESTIGATOR)
Ophthalmic Consultants of BostonBostonMassachusetts02451
Tejinder Kaur
Theodor Sauer, MD (PRINCIPAL_INVESTIGATOR)
Mark Latina, LLCReadingMassachusetts01867
Ann Gardikas
781-942-9876
Mark Latina, MD (PRINCIPAL_INVESTIGATOR)
University of Michigan Kellogg Eye CenterAnn ArborMichigan48105
Lindsay Rudberg
734-647-9196
Amanda Bicket, MD (PRINCIPAL_INVESTIGATOR)
Kresge Eye Institute Wayne State UniversityDetroitMichigan48201
Bayan El-Haik
313-515-5487
Bret Hughes, MD (PRINCIPAL_INVESTIGATOR)
New York Eye Surgery AssociatesThe BronxNew York10469
Krystina Tavarez-Feliciano
347-860-4474
Nathan Radcliffe, MD (PRINCIPAL_INVESTIGATOR)
Cleveland Clinic Cole Eye InstituteClevelandOhio44195
Dusica Vasic
216-445-3840
Ang Li, MD (PRINCIPAL_INVESTIGATOR)
University Hospitals Eye InstituteClevelandOhio44106
Sangeetha Raghupathy
216-844-8552
Douglas Rhee, MD (PRINCIPAL_INVESTIGATOR)
Devers Eye InstitutePortlandOregon97210
Jack Rees
503-413-8495
Robert Kinast, MD (PRINCIPAL_INVESTIGATOR)
Eye Care SpecialistsKingstonPennsylvania18704
Cheryl Bayley
570-714-5915
Daniel Lutz, MD (PRINCIPAL_INVESTIGATOR)
Scheie Eye InstitutePhiladelphiaPennsylvania19104
Criston Young
856-519-8295
Ahmara Ross, MD (PRINCIPAL_INVESTIGATOR)
Wills Eye HospitalPhiladelphiaPennsylvania19107
Meskerem Divers
215-825-4712
Lauren Hock, MD (PRINCIPAL_INVESTIGATOR)
UPMC Eye CenterPittsburghPennsylvania15213-
Vanderbilt Eye InstituteNashvilleTennessee37232
Marybeth Carter
616-936-1639
Rachel Kuchtey, MD (PRINCIPAL_INVESTIGATOR)
Ophthalmology AssociatesFort WorthTexas76102
Kaitlin Sinclair
940-452-1173
Brian Flowers, MD (PRINCIPAL_INVESTIGATOR)
Spokane Eye Clinical ResearchSpokaneWashington99204
Dylan Waidelich
509-623-9768
Rory Allar, MD (PRINCIPAL_INVESTIGATOR)
West Virginia UniversityMorgantownWest Virginia26505
Athena Echols, LPN
304-598-6977
Tony Realini, MD, MPH (PRINCIPAL_INVESTIGATOR)
University of Wisconsin-MadisonMadisonWisconsin53705
Kelly Boyd
608-265-4589
Yao Liu, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Laguna Hills, CA